Lenadomide for sale

I. CHIATAI TIANQING

Pharnex Datamonitor monitoring showed that:

Lenadomide was approved to be listed on the market in Zhengdan. The second domestic generic drug was named Anxian uuuuuuuuuuu The first imitation of Double Heron Pharmaceutical Industry is expected to achieve about 120 million results in 2018. Several competitors hope that the price of drugs will not be too high.

This product was previously listed in six categories of aging drugs. Starting from 2012, the project took seven years to develop. Approved Indications: This product is compatible with dexamethasone in the treatment of previously untreated adult patients with M M who are not suitable for transplantation; this product is compatible with dexamethasone in the treatment of adult patients with M M who have received at least one treatment.

It is reported that the strict BE test of Anxian has been carried out. The test confirms that Anxian is bioequivalent to the original formulation and patient's safety is tolerated. The consistency evaluation test can be applied for and exempted from the market.

2. Lenadomide:

1. Revlimid < (Lenalidomide)

Celgene's annual report shows that the product grew by 17% in 2017, with sales reaching $8.187 billion.

The half-year performance in 2018 was $4.687 billion, an increase of 19.6% over the same period last year. In the first three quarters of 2018, $7.136 billion was spent. The year-round performance is expected to be close to $9.5 billion.

Fierce Pharma predicts that lenalidomide will become the world's highest-selling anti-cancer drug by 2022, with a forecast of $13.4 billion.

2. Under the authorization of Celgene, Baiji Shenzhou sells ABRAXANE paclitaxel for injection (nano-albumin particle-bound), rifamide capsule and Vidaxa for injection (azacytidine for injection) in China.

2018Q1: The company's product revenue comes from sales of ABRAXANE <, Ruifume <, and Vidasa < in China, with sales revenue of $23.25 million in the first quarter of 2018.

2018Q2: The company's product revenue comes from sales of ABRAXANE <, Ruifume <, and Vidasa < in China, with sales revenue of $31.43 million in the second quarter of 2018.

Data agencies predict that the original research of naturamide will sell about 100 million yuan in 2017. Sales performance can be described as poor, I believe that the original research and generic pharmaceutical companies are well aware of the underlying reasons.

3. On July 19, 2017, 36 negotiable drugs, such as lenalidomide, were included in Catalogue B of the National Basic Medical Insurance, Industrial Injury Insurance and Reproductive Insurance Drugs (2017 Edition). The medical insurance payment prices of lenalidomide 10 mg and 25 mg were 866 yuan per pill and 1101.99 yuan per pill, respectively. Prices are still high and health insurance funds are under great pressure.

3, Celgene may be acquired:

Yesterday, after BMS officer Xuan purchased Celgene for $74 billion, our circle of medical friends was brushed on the screen!

US BMS fell sharply and Celgene rose sharply. This Mega-M&A is expected to be completed in Q3 in 2019. It remains to be seen whether Bristol-Myers Squibb will become the king of oncology drugs.